A Critical Nexus:The Clinician and the Researcher.
14 July 2020
As clinician researchers, with busy clinical loads, our greatest challenge is ﬁnding time to engage deeply in the science. But it is necessary to deliver on our research goals.
The nexus between the clinician and the researcher is critical and underpins successful cancer research.
Embedded in every academic clinical cancer service there needs to be a vibrant program of research, which includes basic and translational research. Similarly, embedded in every cancer-related research laboratory, strong links to clinicians at the front line are essential. By working together, clinicians and scientists can gain insights beyond those easily achieved individually.
The clinician and scientist approach the cancer challenge from differing perspectives. Clinicians have a global perspective of the disease enabling them to identify what needs to change for maximal impact. Scientists tend to have a meticulous understanding of speciﬁc steps within complex biological systems - breaking the big picture into smaller parts, thus identifying opportunities for manipulation. Neither can successfully achieve the goal without the other.
This symbiotic relationship is well illustrated by modern cancer immunotherapy. For decades, clinicians recognised that immune manifestations correlated with good outcomes, but it was not until James Allison and Tasuko Honjo identiﬁed critical checkpoints in immune regulation that the opportunity to harness the immune system against cancer was realised. Now, checkpoint inhibitor drug therapies have transformed the cancer ﬁeld, highlighting what can be achieved when clinicians and scientists build upon their respective insights.
Article by Professor Georgina Long AO and Profesor Richard Scolyer, Melanoma Institute Australia and University of Sydney.
Read the full article Voices:Translating Basic Cancer Discoveries to the Clinic in Cancer Cell 37 here
More than $3.5 million in competitive funding grants have been awarded to MIA's researchers.
The ESMO conference provided a platform for announcing a number of key melanoma research findings - including practice-changing research from MIA.
Australian researchers have successfully trialled a combination of new treatments to prevent melanoma from spreading to distant organs.
A new treatment that combines an antibody with a cancer-killing virus improves outcomes for patients with advanced melanoma, an international clinical trial has shown.
It feels like groundhog day - another reality TV show, another batch of blatantly sunburnt contestants.
Wouldn’t it be great if your doctor could know if you would respond to treatment before you even had it?
In our latest research update we showcase research in survival estimates, uncover biomarkers, and reveal practice-changing research in surgery and medical oncology.
Senior Clinical Trial Coordinators, like Sarah Lane, support melanoma patients throughout the clinical trial process.
Melanomas are often hard to differentiate from moles. But new technology is helping to improve accuracy of diagnosis.
We are excited to announce that SunSense will proudly be an official supporter of Melanoma Institute Australia. SunSense is an Australian, family owned business.
Five years ago Julie Randall was diagnosed with melanoma and was given months to live. The melanoma had spread throughout her body. The doctors said it was incurable and she’d be lucky if she survived the next nine months. Julie, a patient at Melanoma Institute Australia under Professor Georgina Long was placed on an experimental drug trial. To watch the entire program, visit 9now.com or click here.
Meet our latest Surgical Oncology Fellow, Eva Nagy, to find out more about life as a surgical oncologist, why she came to MIA and what she hopes to achieve.
Melanoma research at ASCO this year focussed on the more precise use of current treatments to ensure optimal treatment for each patient.
MIA recently demonstrated that reflectance confocal microscopy is a useful tool in the clinic to diagnose suspicious-looking lesions in the mouth.
New research is likely to change the way melanoma is managed in many patients by reducing the need for major surgery and its associated morbidity and cost.
Researchers from MIA will present their latest research findings to the world’s largest oncology conference in early June.
Australian researchers pioneer life-extending treatment for advanced melanoma patients with brain tumours
Australian researchers are the first to demonstrate that patients with advanced melanoma which has spread to the brain can have increased life expectancy and possibly even beat the disease.
Melanoma March 2017 - that's a wrap! Thank you to everyone that helped make it happen.
Thank you so much to all those who contributed in a variety of ways to Melanoma March 2017 in 17 different locations and more around the country! You have contributed to getting the Big Data for Melanoma national Research Project happening!